Flow cytometry solutions provider Cytek Biosciences (Fremont, CA) has completed a Series C funding round co-led by Northern Light Venture Capital (Beijing, China) and 3E Bioventures (Los Altos, CA). The funding will be used to facilitate the expansion of the company's footprint around the world, as well as to ramp up sales, marketing, operations, and global product offerings.
Spurred by the success of its Aurora flow cytometers, which have been sold into four continents, this latest injection of capital underscores the value that the company's innovations are providing to the scientific community.
Feng Deng, founder of Northern Light Venture Capital, will join Cytek's board of directors. Deng has led and backed nearly 200 companies and, prior to forming Northern lights, co-founded NetScreen Technologies, which went public on NASDAQ and was later acquired by Juniper Networks (Sunnyvale, CA) for $4.2 billion. "By bringing a price point to market that lines flow cytometry up for broader adoption, Cytek Biosciences is well positioned to deliver on its promise to make high-end, high-quality flow cytometry accessible to a larger number of researchers and clinicians," Deng notes.
The Cytek Aurora flow cytometer has the goal of making high-quality flow cytometry accessible to a larger number of researchers and clinicians; the Series C funding round will facilitate the expansion of the company's footprint around the world. (Courtesy of Cytek Biosciences)
"Cytek Biosciences' innovative technology brings advanced flow cytometry to both research and clinical markets, especially in the immuno-oncology space," says Dr. Francine Fang, partner at 3E Bioventures. "We believe Aurora will be rapidly adopted into the worldwide market."
Cytek continues to move forward in empowering scientists to obtain deeper insights from a single sample: the company expects to launch several new products before the end of the quarter.
For more information, please visit www.cytekbio.com.